United Therapeutics Corp’s recent filing unveils that its CHAIRPERSON & CEO ROTHBLATT MARTINE A unloaded Company’s shares for reported $0.85 million on Apr 12 ’24. In the deal valued at $235.42 per share,3,600 shares were sold. As a result of this transaction, ROTHBLATT MARTINE A now holds 130 shares worth roughly $30131.4.
Then, ROTHBLATT MARTINE A sold 3,600 shares, generating $860,266 in total proceeds. Upon selling the shares at $238.96, the CHAIRPERSON & CEO now owns 130 shares.
Before that, ROTHBLATT MARTINE A sold 13,800 shares. United Therapeutics Corp shares valued at $3,274,381 were divested by the CHAIRPERSON & CEO at a price of $237.27 per share. As a result of the transaction, ROTHBLATT MARTINE A now holds 130 shares, worth roughly $30131.4.
Goldman upgraded its United Therapeutics Corp [UTHR] rating to a Neutral from a a Sell in a research note published on February 12, 2024; the price target was increased to $215 from $213. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Wells Fargo began covering UTHR with “an Overweight” recommendation on December 08, 2023. UBS started covering the stock on December 06, 2022. It rated UTHR as “a Buy”.
Price Performance Review of UTHR
On Tuesday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock fall -1.40% to $231.78. Over the last five days, the stock has lost -2.22%. United Therapeutics Corp shares have risen nearly 5.41% since the year began. Nevertheless, the stocks have risen 1.34% over the past one year. While a 52-week high of $261.54 was reached on 03/26/24, a 52-week low of $204.44 was recorded on 02/08/24. SMA at 50 days reached $229.87, while 200 days put it at $229.11. A total of 0.5 million shares were traded, compared to the trading of 0.42 million shares in the previous session.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 230.08, which if violated will result in even more drops to 228.37. On the upside, there is a resistance level at 233.80. A further resistance level may holdings at 235.81. The Relative Strength Index (RSI) on the 14-day chart is 46.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.92, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 63.59%. Stochastics %K at 40.08% indicates the stock is a holding.
The most recent change occurred on December 05, 2022 when Goldman began covering the stock and recommended ‘”a Sell”‘ rating along with a $230 price target.
